Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: A case report

Chemotherapy

Volumn 59, Issue 1, 2013, Pages 74-78

  Nakayama, Yusuke ^a   Ikeda, Masafumi ^a   Kojima, Motohiro ^a   Goto, Koichi ^a   Hara, Miyuki ^a   Okuyama, Hiroyuki ^a   Takahashi, Hideaki ^a   Ohno, Izumi ^a   Shimizu, Satoshi ^a   Mitsunaga, Shuichi ^a   Okusaka, Takuji ^b  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Everolimus; Interstitial lung disease; Neuroendocrine tumor; Pancreas

Indexed keywords

CORTICOSTEROID; EVEROLIMUS; OCTREOTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD56 ANTIGEN; CHROMOGRANIN A; KI 67 ANTIGEN; KREBS VON DEN LUNGEN 6; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LIVER BIOPSY; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TUMOR BIOPSY; TUMOR GROWTH; ABDOMINAL RADIOGRAPHY; COMMON COLD; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOPLASM; DIARRHEA; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEVER; FOLLOW UP; GENERAL CONDITION DETERIORATION; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG INFILTRATE; MIDDLE AGED; OXYGEN SATURATION; PANCREAS TUMOR; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 84880183246     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000351103     Document Type: Article

References (16)

1. Muro K: mTOR inhibitor. Jpn J Cancer Chemother 2011; 38: 7-11.
2. Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
3. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
4. Tsukamoto T, Shinohara N, Tsuchiya N, et al: Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2011; 41: 17-24.
5. Bosman F, Camerio F, Hurban R, Theise N: WHO Classification of Tumours of the Digestive System. Lyon, IARC Press, 2010.
6. Mizuno R, Asano K, Mikami S, Nagata H, Kaneko G, Oya M: Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2012; 42: 442-446.
7. White DA, Camus P, Endo M, et al: Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396-403.
8. Akata K, Yatera K, Ishimoto H, et al: Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma. Intern Med 2011; 50: 3013-3017.
9. White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH: Characterization of pneumonitis in patients with advanced nonsmall cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 2009; 4: 1357-1363.
10. Ellard SL, Clemons M, Gelmon KA, et al: Randomized phase II study comparing two schedules of everolimus in patients with recurrent/ metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-4541.
11. Barber NA, Ganti AK: Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011; 6: 235-243.
12. Huober J, Schoch O, Templeton A, et al: Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy 2010; 56: 69-70.
13. Hochstrasser A, Benz G, Joerger M, et al: Interstitial pneumonitis after treatment with pemetrexed: a rare event? Chemotherapy 2012; 58: 84-88.
14. Porta C, Osanto S, Ravaud A, et al: Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47: 1287-1298.
15. Ishikawa N, Hattori N, Yokoyama A, et al: Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig 2012; 50: 3-13.
16. Ohnishi H, Yokoyama A, Yasuhara Y, et al: Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003; 58: 872-875. (Pubitemid 37239235)